세계의 분자 감염증 검사 시장 : 제품/서비스별, 유형별, 검사 유형별, 질병별, 기술별, 최종사용자별 - 예측(-2029년)

The molecular infectious disease testing market is projected to reach USD 17.78 billion in 2029 from an estimated value of USD 9.37 billion in 2024 at a CAGR of 13.7% during the forecast period. Rapid advancements in molecular diagnostic technologies are the main driving force in the molecular infectious disease testing market. Advancements in PCR, next-generation sequencing, and other technologies enhance test accuracy, speed of completion, and efficiency, making them more accessible at lower costs. Moreover, market players continue to develop high- end automated diagnostic platforms which further improves the workflow and increases diagnostic capabilities. This leads to accurate and timely diagnosis of infectious diseases, improved patient results, and improved surveillance of newly emerging pathogens. Through this, providers can make timely decisions, increasing the adoption rate of molecular diagnostics for infectious disease testing.

"Laboratory tests segment is expected to witness the fastest growth rate in the molecular infectious disease testing market, by test type, during the forecast period."

Based on test type, the molecular infectious disease testing market can be divided into laboratory tests and point of care tests. Laboratory tests are the fastest-growing segment by test type in the molecular infectious disease testing market because of their high accuracy, scalability, and ability to handle all types of pathogens. These tests, including PCR and sequencing-based diagnostics, are widely used in hospitals and diagnostic laboratories for their precision in discovering infections. With the advances in laboratory automation and high-throughput technologies, turnaround times have decreased significantly, thereby making the laboratory-based molecular tests very efficient. Moreover, the need for extensive diagnostic panels that allow detection of multiple infections in one test further enhances the preference for laboratory-based solutions. With high reliability and the capability to address complex diagnostic needs, laboratory tests are the preferred solution for healthcare providers.

"Multiplex testing segment accounted for the largest market share in the molecular infectious disease testing market, by type, in 2023."

Based on type, the molecular infectious disease testing market is bifurcated into singleplex testing and multiplex testing. The multiplex testing segment leads the molecular infectious disease testing market due to the capability of its ability to perform multiple tests for detecting and differentiating several pathogens in a single test. This efficiency cuts down time, costs, and resources for diagnosis, thus becoming one of the most preferred options by healthcare providers. All these factors together with the rise in co-infections, necessity for thorough diagnosis solutions, and demand for timely and accurate results have increased the multiplex testing market. In addition, new technology improvements include greater assay sensitivity and the introduction of user-friendly platforms that support widespread use of multiplex testing in hospitals and diagnostic labs.

"Asia Pacific: The fastest-growing market for molecular infectious disease testing"

The worldwide market for molecular infectious disease testing is categorized into North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries. The Asia Pacific region is experiencing significant growth in the molecular infectious disease testing market driven by the growing incidence of infectious diseases in the densely populated countries, together with growing awareness of the early detection of diseases, which has created a demand for more advanced diagnostics. Governments and healthcare organizations throughout the region are investing heavily to improve healthcare infrastructure, expand diagnostic capabilities, and support research initiatives. Moreover, growing emphasis on diseases surveillance and outbreak management and rising healthcare spending position Asia Pacific as one of the big contributors to growth in the entire market.

The break-up of the profile of primary participants in the molecular infectious disease testing market:

• By Company Type: Tier 1 - 40%, Tier 2 - 30%, and Tier 3 - 30%
• By Designation: C-level - 27%, D-level - 18%, and Others - 55%
• By Region: North America - 51%, Europe - 21%, Asia Pacific - 18%, Latin America - 6%, and Middle East & Africa- 4%

The key players in this market are Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMerieux (France), Hologic, Inc. (US), Abbott (US), Thermo Fisher Scientific Inc. (US), QIAGEN (Netherands), Revvity (US), Siemens Healthineers AG (Germany), BD (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Bruker (US), Seegene Inc. (South Korea), Genetic Signatures (Australia), Co-Diagnostics, Inc. (US), Savyon Diagnostics (Israel), Vela Diagnostics (Singapore), Molbio Diagnostics Pvt. Ltd. (India), Uniogen OY (Finland), geneOmbio Technologies (India), Advanced Molecular Diagnostics (UK), GeneFirst Limited (UK), and altona Diagnostics GmbH (Germany).

Research Coverage:

This research report categorizes the molecular infectious disease testing market by product & service (reagents & kits, instruments, and services & software), by type (singleplex testing and multiplex testing), by test type (laboratory tests and point of car tests), by disease (respiratory infectious diseases (influenza, tuberculosis, pharyngitis, and other respiratory infectious diseases), gastrointestinal infectious diseases (hepatitis and other gastrointestinal infectious diseases), sexually transmitted diseases (human immunodeficiency virus, chlamydia trachomatis, neisseria gonorrhoea, syphilis, human papillomavirus, and other sexually transmitted diseases), vaginitis, meningitis, vector borne diseases, hospital-acquired infections, and other infectious diseases), by technology (polymerase chain reaction, in situ hybridization, isothermal nucleic acid amplification technology, DNA sequencing & next generation sequencing, DNA microarrays, and other technologies), by end user (diagnostic laboratories, hospitals & clinics, and other end users) and region (North America, Europe, Asia Pacific, Latin America, Middle East & Africa, and the GCC countries). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges influencing the growth of the molecular infectious disease testing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, acquisitions, and agreements. New product & service launches, and recent developments associated with the molecular infectious disease testing market. Competitive analysis of upcoming startups in the molecular infectious disease testing market ecosystem is covered in this report.

Reasons to buy this report:

The report will help the market leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall molecular infectious disease testing market and the subsegments. This report will help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the market and provides them with information on key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

• Analysis of key drivers (Rising burden of infectious diseases, rapid technological advancements in molecular diagnostics, growing funding for molecular testing), opportunities (High growth opportunities in emerging economies), restraints (Inconsistent reimbursement policies), and challenges (Changing regulatory landscape, operational barriers and labor shortage) influencing the growth of the molecular infectious disease testing market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the molecular infectious disease testing market.
• Market Development: Comprehensive information about lucrative markets - the report analyses the molecular infectious disease testing market across varied regions.
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the molecular infectious disease testing market.
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings of leading players like Danaher (US), F. Hoffmann-La Roche Ltd (Switzerland), bioMerieux (France), Hologic, Inc. (US), and Abbott (US).

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
• 2.2 RESEARCH APPROACH
  • 2.2.1 SECONDARY RESEARCH
    • 2.2.1.1 Key secondary sources
    • 2.2.1.2 Key data from secondary sources
    • 2.2.1.3 Objectives of secondary research
  • 2.2.2 PRIMARY RESEARCH
    • 2.2.2.1 Key primary sources
    • 2.2.2.2 Key data from primary sources
    • 2.2.2.3 Objectives of primary research
    • 2.2.2.4 Key industry insights
    • 2.2.2.5 Breakdown of primary interviews
• 2.3 MARKET SIZE ESTIMATION
  • 2.3.1 BOTTOM-UP APPROACH
    • 2.3.1.1 Company revenue estimation approach
    • 2.3.1.2 Presentations of companies and primary interviews
    • 2.3.1.3 Estimation of total molecular-based tests for HIV in US
    • 2.3.1.4 Growth forecast model
    • 2.3.1.5 CAGR projections
  • 2.3.2 TOP-DOWN APPROACH
• 2.4 DATA TRIANGULATION
• 2.5 MARKET SHARE ANALYSIS
• 2.6 RESEARCH ASSUMPTIONS
  • 2.6.1 PARAMETRIC ASSUMPTIONS
  • 2.6.2 GROWTH RATE ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 MOLECULAR INFECTIOUS DISEASE TESTING MARKET OVERVIEW
• 4.2 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029
• 4.3 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2024 VS. 2029
• 4.4 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE, 2024 VS. 2029
• 4.5 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE, 2024 VS. 2029
• 4.6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY, 2024 VS. 2029
• 4.7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER, 2024 VS. 2029
• 4.8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Rising burden of infectious diseases
    • 5.2.1.2 Rapid technological advancements in molecular diagnostics
    • 5.2.1.3 Growing funding for molecular testing
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Inconsistent reimbursement policies
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 High growth opportunities in emerging economies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Changing regulatory landscape
    • 5.2.4.2 Operational barriers and labor shortage issues
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE SELLING PRICE TREND, BY PRODUCT
  • 5.4.2 INDICATIVE SELLING PRICE TREND OF SEXUALLY TRANSMITTED DISEASE TESTS, BY KEY PLAYER
  • 5.4.3 INDICATIVE SELLING PRICE TREND OF GASTROINTESTINAL DISEASE TESTS, BY KEY PLAYER
  • 5.4.4 INDICATIVE SELLING PRICE TREND, BY REGION
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Polymerase chain reaction
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 Isolated nucleic acid amplification technology
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 Next-generation sequencing
• 5.10 PATENT ANALYSIS
• 5.11 TRADE ANALYSIS
  • 5.11.1 IMPORT DATA FOR HS CODE 3822
  • 5.11.2 EXPORT DATA FOR HS CODE 3822
• 5.12 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.13 CASE STUDY ANALYSIS
  • 5.13.1 CASE STUDY 1: IMPROVED PATHOGEN-DIRECTED TREATMENT THROUGH RAPID SYNDROMIC PCR TESTING
  • 5.13.2 CASE STUDY 2: CLINICAL IMPACT OF MULTIPLEX MOLECULAR DIAGNOSTIC TESTING IN CHILDREN WITH ACUTE GASTROENTERITIS
  • 5.13.3 CASE STUDY 3: IMPACT OF MOLECULAR POINT OF CARE TESTING FOR GROUP A STREPTOCOCCUS PHARYNGITIS
• 5.14 REGULATORY LANDSCAPE
  • 5.14.1 REGULATORY ANALYSIS
    • 5.14.1.1 NORTH AMERICA
      • 5.14.1.1.1 US
      • 5.14.1.1.2 Canada
    • 5.14.1.2 EUROPE
      • 5.14.1.2.1 Germany
      • 5.14.1.2.2 UK
      • 5.14.1.2.3 France
      • 5.14.1.2.4 Italy
    • 5.14.1.3 ASIA PACIFIC
      • 5.14.1.3.1 China
      • 5.14.1.3.2 Japan
      • 5.14.1.3.3 India
      • 5.14.1.3.4 Australia
    • 5.14.1.4 LATIN AMERICA
      • 5.14.1.4.1 Brazil
      • 5.14.1.4.2 Mexico
    • 5.14.1.5 MIDDLE EAST
      • 5.14.1.5.1 Africa
  • 5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.15 PORTER'S FIVE FORCES ANALYSIS
  • 5.15.1 BARGAINING POWER OF SUPPLIERS
  • 5.15.2 BARGAINING POWER OF BUYERS
  • 5.15.3 THREAT OF NEW ENTRANTS
  • 5.15.4 THREAT OF SUBSTITUTES
  • 5.15.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.16.2 BUYING CRITERIA
• 5.17 IMPACT OF AI ON MOLECULAR INFECTIOUS DISEASE TESTING MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING APPLICATIONS
  • 5.17.3 AI USE CASES
  • 5.17.4 KEY COMPANIES IMPLEMENTING AI
  • 5.17.5 FUTURE OF AI IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET

6 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY PRODUCT & SERVICE

• 6.1 INTRODUCTION
• 6.2 REAGENTS & KITS
  • 6.2.1 ONGOING INNOVATIONS IN MOLECULAR DIAGNOSTICS TO SPUR GROWTH
• 6.3 INSTRUMENTS
  • 6.3.1 RISING PREVALENCE OF INFECTIOUS DISEASES TO FOSTER GROWTH
• 6.4 SERVICES & SOFTWARE
  • 6.4.1 INCREASING UPTAKE OF ADVANCED INSTRUMENTS TO FACILITATE GROWTH

7 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 MULTIPLEX TESTING
  • 7.2.1 RISING DEMAND FOR FASTER DIAGNOSIS TO PROMOTE GROWTH
• 7.3 SINGLEPLEX TESTING
  • 7.3.1 NEED FOR AFFORDABLE AND USER-FRIENDLY TESTING TO AUGMENT GROWTH

8 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TEST TYPE

• 8.1 INTRODUCTION
• 8.2 LABORATORY TESTS
  • 8.2.1 INCREASING NEED FOR AUTOMATION TO FAVOR GROWTH
• 8.3 POINT OF CARE TESTS
  • 8.3.1 GROWING AWARENESS ABOUT DISEASE SURVEILLANCE, SCREENING, AND OUTBREAK RESPONSE TO DRIVE MARKET

9 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY DISEASE

• 9.1 INTRODUCTION
• 9.2 RESPIRATORY INFECTIOUS DISEASES
  • 9.2.1 INFLUENZA
    • 9.2.1.1 Growing focus on faster diagnosis and control to propel market
  • 9.2.2 TUBERCULOSIS
    • 9.2.2.1 Rise in undiagnosed and untreated cases to promote growth
  • 9.2.3 PHARYNGITIS
    • 9.2.3.1 Need to differentiate between bacterial and viral infections to fuel growth
  • 9.2.4 OTHER RESPIRATORY INFECTIOUS DISEASES
• 9.3 GASTROINTESTINAL INFECTIOUS DISEASES
  • 9.3.1 HEPATITIS
    • 9.3.1.1 Rising government initiatives to expedite growth
  • 9.3.2 OTHER GASTROINTESTINAL INFECTIOUS DISEASES
• 9.4 SEXUALLY TRANSMITTED DISEASES
  • 9.4.1 HUMAN IMMUNODEFICIENCY VIRUS
    • 9.4.1.1 Increasing number of blood transfusions and blood donations to augment growth
  • 9.4.2 HUMAN PAPILLOMAVIRUS
    • 9.4.2.1 Technological advancements for preventing human papillomavirus infections to drive market
  • 9.4.3 CHLAMYDIA TRACHOMATIS
    • 9.4.3.1 Increasing development of molecular tests to aid growth
  • 9.4.4 NEISSERIA GONORRHOEAE
    • 9.4.4.1 Increasing development of novel assays to boost market
  • 9.4.5 SYPHILIS
    • 9.4.5.1 Growing demand for affordable and rapid molecular diagnostic solutions to drive market
  • 9.4.6 OTHER SEXUALLY TRANSMITTED DISEASES
• 9.5 HOSPITAL-ACQUIRED INFECTIONS
  • 9.5.1 GROWING BURDEN OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS TO FUEL MARKET
• 9.6 VAGINITIS
  • 9.6.1 INCREASING AWARENESS ABOUT WOMEN'S HEALTH TO BOLSTER GROWTH
• 9.7 MENINGITIS
  • 9.7.1 RISING INCIDENCE OF INVASIVE MENINGOCOCCAL DISEASE TO ASSIST GROWTH
• 9.8 VECTOR-BORNE DISEASES
  • 9.8.1 GROWING FOCUS ON DISEASE SURVEILLANCE TO PROPEL MARKET
• 9.9 OTHER INFECTIOUS DISEASES

10 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY TECHNOLOGY

• 10.1 INTRODUCTION
• 10.2 POLYMERASE CHAIN REACTION
  • 10.2.1 NEED FOR HIGH PRECISION FOR DISEASE IDENTIFICATION TO SUPPORT GROWTH
• 10.3 ISOTHERMAL NUCLEIC ACID AMPLIFICATION TECHNOLOGY
  • 10.3.1 EMERGENCE OF NEW PATHOGENS TO STIMULATE GROWTH
• 10.4 DNA SEQUENCING & NEXT-GENERATION SEQUENCING
  • 10.4.1 GROWING APPLICATIONS IN DIAGNOSING BACTERIAL, VIRAL, FUNGAL, AND PARASITIC INFECTIONS TO DRIVE MARKET
• 10.5 IN SITU HYBRIDIZATION
  • 10.5.1 NEED FOR SAFER AND MORE PRACTICAL TESTING IN CLINICAL SETTINGS TO FUEL MARKET
• 10.6 DNA MICROARRAYS
  • 10.6.1 NEED FOR AFFORDABLE AND SENSITIVE DETECTION TO ENCOURAGE GROWTH
• 10.7 OTHER TECHNOLOGIES

11 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 DIAGNOSTIC LABORATORIES
  • 11.2.1 GROWING EMPHASIS ON QUALITY CONTROL AND STANDARDIZED TESTING PROTOCOLS TO BOOST MARKET
• 11.3 HOSPITALS & CLINICS
  • 11.3.1 RISING PATIENT VOLUME TO CONTRIBUTE TO GROWTH
• 11.4 OTHER END USERS

12 MOLECULAR INFECTIOUS DISEASE TESTING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 Presence of advanced healthcare infrastructure to augment growth
  • 12.2.3 CANADA
    • 12.2.3.1 Favorable government initiatives to fuel market
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Increasing healthcare expenditure to advance growth
  • 12.3.3 UK
    • 12.3.3.1 Growing number of diagnostic centers to fuel market
  • 12.3.4 FRANCE
    • 12.3.4.1 Increasing demand for early disease diagnosis to augment growth
  • 12.3.5 ITALY
    • 12.3.5.1 Growing adoption of advanced diagnostic technologies to fuel market
  • 12.3.6 RUSSIA
    • 12.3.6.1 Increasing access to quality healthcare to facilitate growth
  • 12.3.7 SPAIN
    • 12.3.7.1 Growing public health initiatives to boost market
  • 12.3.8 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Rising public access to modern healthcare to spur growth
  • 12.4.3 JAPAN
    • 12.4.3.1 Universal healthcare reimbursement policy to foster growth
  • 12.4.4 INDIA
    • 12.4.4.1 Increased private and public investments to bolster growth
  • 12.4.5 AUSTRALIA
    • 12.4.5.1 Growing investments for testing centers and treatment facilities to drive market
  • 12.4.6 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Growing focus on improving healthcare infrastructure to fuel market
  • 12.5.3 MEXICO
    • 12.5.3.1 Increasing accessibility and affordability of healthcare services to foster growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST & AFRICA
  • 12.6.1 BOOMING HEALTHCARE INVESTMENTS TO AID GROWTH
  • 12.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
• 12.7 GCC COUNTRIES
  • 12.7.1 GROWING PUBLIC HEALTHCARE FUNDING TO DRIVE MARKET
  • 12.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 13.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN MOLECULAR INFECTIOUS DISEASE TESTING MARKET
• 13.3 REVENUE ANALYSIS, 2021-2023
• 13.4 MARKET SHARE ANALYSIS, 2023
• 13.5 MARKET SHARE ANALYSIS OF EMEA REGION, 2023
• 13.6 COMPANY VALUATION AND FINANCIAL METRICS
• 13.7 BRAND/PRODUCT COMPARISON
• 13.8 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 13.8.1 STARS
  • 13.8.2 EMERGING LEADERS
  • 13.8.3 PERVASIVE PLAYERS
  • 13.8.4 PARTICIPANTS
  • 13.8.5 COMPANY FOOTPRINT, KEY PLAYERS, 2023
    • 13.8.5.1 Company footprint
    • 13.8.5.2 Region footprint
    • 13.8.5.3 Product & service footprint
    • 13.8.5.4 Test type footprint
    • 13.8.5.5 Disease footprint
• 13.9 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 13.9.1 PROGRESSIVE COMPANIES
  • 13.9.2 RESPONSIVE COMPANIES
  • 13.9.3 DYNAMIC COMPANIES
  • 13.9.4 STARTING BLOCKS
  • 13.9.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2023
    • 13.9.5.1 Detailed list of key startups/SMEs
    • 13.9.5.2 Competitive benchmarking of startups/SMEs
• 13.10 COMPETITIVE SCENARIO
  • 13.10.1 PRODUCT LAUNCHES AND APPROVALS
  • 13.10.2 DEALS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 DANAHER
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches and approvals
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Right to win
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses and competitive threats
  • 14.1.2 F. HOFFMANN-LA ROCHE LTD
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches and approvals
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Right to win
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses and competitive threats
  • 14.1.3 BIOMERIEUX
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches and approvals
      • 14.1.3.3.2 Deals
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Right to win
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses and competitive threats
  • 14.1.4 HOLOGIC, INC.
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches and approvals
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Right to win
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses and competitive threats
  • 14.1.5 ABBOTT
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches and approvals
      • 14.1.5.3.2 Deals
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Right to win
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses and competitive threats
  • 14.1.6 THERMO FISHER SCIENTIFIC INC.
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches and approvals
      • 14.1.6.3.2 Deals
  • 14.1.7 QIAGEN
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Product launches and approvals
      • 14.1.7.3.2 Deals
      • 14.1.7.3.3 Expansions
  • 14.1.8 REVVITY
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products offered
  • 14.1.9 GRIFOLS, S.A.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Product launches and approvals
      • 14.1.9.3.2 Deals
  • 14.1.10 SEEGENE INC.
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products offered
    • 14.1.10.3 Recent developments
      • 14.1.10.3.1 Product launches and approvals
      • 14.1.10.3.2 Deals
      • 14.1.10.3.3 Expansions
  • 14.1.11 DIASORIN S.P.A.
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches and approvals
      • 14.1.11.3.2 Deals
  • 14.1.12 SIEMENS HEALTHINEERS AG
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Product launches and approvals
      • 14.1.12.3.2 Deals
      • 14.1.12.3.3 Expansions
  • 14.1.13 BD
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products offered
    • 14.1.13.3 Recent developments
      • 14.1.13.3.1 Product launches and approvals
      • 14.1.13.3.2 Deals
      • 14.1.13.3.3 Expansions
• 14.2 OTHER PLAYERS
  • 14.2.1 QUIDELORTHO CORPORATION
  • 14.2.2 BRUKER
  • 14.2.3 GENETIC SIGNATURES
  • 14.2.4 CO-DIAGNOSTICS, INC.
  • 14.2.5 VELA DIAGNOSTICS
  • 14.2.6 MOLBIO DIAGNOSTICS PVT. LTD.
  • 14.2.7 SAVYON DIAGNOSTICS
  • 14.2.8 UNIOGEN OY
  • 14.2.9 GENEOMBIO TECHNOLOGIES
  • 14.2.10 ADVANCED MOLECULAR DIAGNOSTICS
  • 14.2.11 ALTONA DIAGNOSTICS GMBH
  • 14.2.12 GENEFIRST LIMITED

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS